Dr. Rampal on the Potential Utilization of Navtemadlin in Relapsed/Refractory AML and MPNs
July 6th 2022Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.
Read More
Dr. Rampal on the Investigation of Navtemadlin in Relapsed/Refractory AML and MPNs
June 4th 2022Raajit K. Rampal, MD, PhD, discusses the investigation of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.
Read More